EPIZYME INC's ticker is EPZM and the CUSIP is 29428V104. A total of 89 filers reported holding EPIZYME INC in Q4 2015. The put-call ratio across all filers is 0.33 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $8,499,000 | +41.4% | 478,793 | -0.1% | 0.02% | +47.1% |
| Q4 2017 | $6,012,000 | -49.9% | 479,053 | -23.9% | 0.02% | -51.4% |
| Q3 2017 | $11,995,000 | +23.3% | 629,666 | -2.2% | 0.04% | +20.7% |
| Q2 2017 | $9,726,000 | +678.1% | 644,081 | +725.3% | 0.03% | +625.0% |
| Q4 2015 | $1,250,000 | -19.3% | 78,041 | -35.2% | 0.00% | -20.0% |
| Q3 2015 | $1,548,000 | -80.4% | 120,363 | -63.4% | 0.01% | -76.2% |
| Q2 2015 | $7,892,000 | +382.1% | 328,871 | +277.4% | 0.02% | +425.0% |
| Q1 2015 | $1,637,000 | -21.9% | 87,134 | -21.6% | 0.00% | -20.0% |
| Q4 2014 | $2,097,000 | -89.9% | 111,114 | -85.5% | 0.01% | -90.4% |
| Q3 2014 | $20,792,000 | -8.9% | 766,965 | +4.6% | 0.05% | +100.0% |
| Q2 2014 | $22,826,000 | +841.7% | 733,502 | +589.1% | 0.03% | +333.3% |
| Q1 2014 | $2,424,000 | +9.1% | 106,436 | -0.3% | 0.01% | +20.0% |
| Q4 2013 | $2,221,000 | -49.1% | 106,772 | -1.9% | 0.01% | -50.0% |
| Q3 2013 | $4,367,000 | – | 108,820 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 31,833,334 | $47,750,000 | 19.42% |
| MPM BioImpact LLC | 3,425,202 | $3,939,000 | 1.06% |
| Palo Alto Investors LP | 6,774,541 | $7,791,000 | 0.60% |
| Foresite Capital Management I, LLC | 143,759 | $165,000 | 0.29% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 6,603,870 | $7,594,000 | 0.23% |
| Rock Springs Capital Management LP | 7,267,696 | $8,358,000 | 0.21% |
| BP PLC | 24,687 | $28,000 | 0.16% |
| NewGen Asset Management Ltd | 250,000 | $288,000 | 0.13% |
| GSA CAPITAL PARTNERS LLP | 467,836 | $538,000 | 0.07% |
| Frazier Life Sciences Management, L.P. | 739,369 | $850,000 | 0.07% |